Citocline in the treatment of acute ischaemic stroke: an international, randomized, multicentre, placebo-controlled study (ICTUS trial)

Is the use of Citocline is beneficial for acute ischaemic stroke?

Fauzia Nomani, Ayesha Kamran Kamal

Stroke is the leading cause of disability in the world population. Citocline is an exogenous form of cytidine 5'-diphosphatecholine, an important component of the cellular membrane, is a medication believed to have combined neurovascular protection and repair effects. It is extensively studied in many clinical trials in patients including ischaemic stroke however promising results on meaningful clinical recovery and reduction of disability is lacking.

What was the trial?

ICTUS trial was an international randomized multicentre placebo-controlled trial to confirm the results of pooled data in a large clinical trial available on the effect of Citocline on the recovery of patients with moderate to severe acute ischaemic stroke at 3 months.

Who were patients and what was the intervention?

A total of 2298 patients from centers in Europe were recruited during a period of six years. Patients had moderate to severe anterior circulation stroke categorized by the use of 3 scales (NIHSS, modified Rankin score, Barthel index) for neurological impairment & functional disability along with the physical examination & radiological evidence. Patients were randomly assigned to two groups. Treatment group was given 2000mg/day of Citocline initially intravenous then oral for a total of 6 weeks, in a double blinded fashion. rt-PA was used if required in both groups. Both groups were comparable in term of age, gender, time from stroke onset.

What were the results?

Primary outcome e.g. global recovery at 90 days was similar in both groups with adjusted odds ratio for primary outcome was 10.3(95% CI). Secondary objective (rate of favourable response on single scale) showed no difference with the treatment with citocline.

What were the conclusions?

The author concluded that the trial failed to prove any benefit of Citocline treatment in the recovery from ischaemic stroke in 90 days. Although previous Metaanalysis showed some benefit of the treatment with citocline.

Why is this important?

Citocline adds no clinical improvement to the patient’s clinical condition and is not a feasible choice for patients; rather it increases the cost of care. In a resource poor region these resources should be rationally utilized.

Acknowledgement and Disclosure Statement

The International Cerebrovascular Translational Clinical Research and Training Program (ICT_CRT) at the Aga Khan University is supported by funds from the Award Number D43TW008660 from the Fogarty International Center and the National Institute of Neurologic Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Fogarty International Center or the National Institutes of Health.

Recommended Reading